ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/VEGFR2-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/VEGFR2-inhibitor
5
trial(s) found.
NCT05691478
Advanced
Phase 2 / Phase 3
Recruiting
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (
NCI-2022-08567
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Osteosarcoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
2031 - Randwick - Sydney Children's Hospital (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ VEGFR2 inhibitor
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Glandore - Ashford Cancer Centre
NCT05327686
Radonc
Phase 2
Recruiting
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (
SAMURAI
)
radiotherapy
+ VEGFR2 inhibitor
Clear cell renal cell carcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ VEGFR2 inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12616001187437
Advanced
Phase 2
Not recruiting
Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing. (
MatchMel
)
ALK/ROS1/IGF1R inhibitor
ALK inhibitor
ALK inhibitor,first generation
ALK inhibitor,second generation
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,first generation
BCR-ABL1 inhibitor,second generation
Bortezomib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Cabozantinib
Ceritinib
Crizotinib
Dasatinib
EGFR inhibitor
EGFR inhibitor,first generation
EGFR inhibitor,type II
ERBB2 inhibitor
ERBB2 inhibitor,first generation
Erlotinib
Everolimus
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
FLT3 inhibitor
Gefitinib
HDAC inhibitor
IGF1R inhibitor
Imatinib
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,ATP-competitive
KIT inhibitor,first generation
Lapatinib
MEK inhibitor
MET inhibitor
MET inhibitor,type 1
MET inhibitor,type 2
Nilotinib
Olaparib
PARP inhibitor
PDGFRA inhibitor
PDGFR inhibitor
Palbociclib
Pazopanib
RAF inhibitor
RET inhibitor
ROS1 inhibitor
Ramucirumab
Regorafenib
SRC inhibitor
Sorafenib
Sunitinib
Trametinib
VEGFR2 inhibitor
VEGFR inhibitor
Vorinostat
YES1 inhibitor
anti-VEGFR2 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,AXL-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,ERBB2-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,FLT3-targeting
cancer therapy,HDAC-targeting
cancer therapy,IGF1R-targeting
cancer therapy,KIT-targeting
cancer therapy,MEK-targeting
cancer therapy,MET-targeting
cancer therapy,PARP-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,RAF-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,VEGFR2-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,proteasome-targeting
immuno-oncology therapy,VEGFR2-targeting
mTORC1 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
proteasome inhibitor
+ VEGFR2 inhibitor
Melanoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Enrolling by invitation (1)
Not recruiting (1)
Recruitment Country and State
NSW (4)
VIC (4)
NZ (2)
QLD (2)
SA (2)
WA (1)
Phase
Phase 1 (1)
Phase 2 (2)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Advanced (4)
Radonc (1)
Cancer Therapy Class
KIT
100%
RET
100%
VEGFR
100%
VEGFR2
100%
AXL
80%
MET
80%
ROS1
80%
PD-1
60%
PD-1/PD-L1
60%
PDGFR
60%
VEGF
40%
ERBB2
40%
PARP
40%
HIF2a
20%
CTLA4
20%
PD-L1
20%
HPK1
20%
LAG3
20%
OX40
20%
TIGIT
20%
VEGFR1
20%
VEGFR3
20%
ALK
20%
BCR-ABL1
20%
CDK4
20%
CDK6
20%
CRAF
20%
EGFR
20%
FGFR1
20%
FGFR1/2/3
20%
FGFR2
20%
FGFR3
20%
FGFR4
20%
FLT3
20%
HDAC
20%
IGF1R
20%
MEK
20%
PDGFRA
20%
RAF
20%
SRC
20%
YES1
20%
mTOR
20%
mTORC1
20%
proteasome
20%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2109 - North Ryde - Macquarie University Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
5037 - Glandore - Ashford Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3168 - Clayton - Monash Medical Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
Cancer Type
Cancer
Solid tumour
Clear cell renal cell carcinoma
Kidney cancer
Urogenital cancer
Bone cancer
Osteosarcoma
Sarcoma
Melanoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy